SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Passage Bio reported updated Phase 1/2 data showing PBFT02 reduced…

Passage Bio · PRESS-RELEASE filed Apr 20, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 20, 2026 at 07:00 ET

Passage Bio reported updated Phase 1/2 data showing PBFT02 reduced brain atrophy and stabilized plasma NfL in early-stage FTD-GRN patients, but the FDA has mandated a randomized controlled trial for approval, creating ethical and financial hurdles. The company has initiated a strategic review to evaluate alternatives, including a potential sale or partnership, amid development challenges.

  • PBFT02 reduced whole brain atrophy by 64% and frontotemporal cortex atrophy by 54% in CDR 1 patients vs. natural history.
  • Plasma NfL levels stabilized in treated patients vs. significant increase in untreated natural history cohort.
  • FDA requires a randomized controlled trial for registrational approval, rejecting a single-arm design.
  • Company has initiated a strategic review of alternatives, including M&A, asset sale, or licensing, with Wedbush PacGrow as advisor.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access